Eingabe löschen

Kopfbereich

Schnellnavigation

Hauptnavigation

Dr. Steffi Lehmann

Dr. Steffi Lehmann

Dr. Steffi Lehmann
ZHAW Life Sciences und Facility Management
Fachgruppe Pharmazeutische Technologie und Pharmakologie
Einsiedlerstrasse 31
8820 Wädenswil

+41 (0) 58 934 50 64
steffi.lehmann@zhaw.ch

Persönliches Profil

Tätigkeit an der ZHAW als

Fachgruppenleiterin Pharmakologie/Pharmazeutische Technologie

http://https://www.zhaw.ch/de/lsfm/institute-zentren/icbt/pharmazeutische-wirkstoffforschung-und-arzneimittelentwicklung/pharmazeutische-technologie-und-pharmakologie/

Arbeits- und Forschungsschwerpunkte, Spezialkenntnisse

- preclinical pharmacology
- in vitro and in vivo molecular imaging
- cancer research
- hypoxic signaling in cancer

Aus- und Fortbildung

02/2006-08/2010
Ph.D. studies at the Institute for Biomedical Engineering, supervision: Prof. Markus Rudin; title of thesis: “Multi-modal in vivo imaging of tumor hypoxia and its downstream molecular events”

08/2008-12/2008
School of Journalism (MAZ) Lucerne, Certificate of advanced studies (CAS) in Science Journalism

04/2005-10/2005
ETH Zurich: Master in Biochemistry with main subjects Molecular Biology, Biochemistry, Biological Chemistry and Cell Biology


Beruflicher Werdegang

08/2014-07/2018
ETH and University of Zurich: Institute for Biomedical Engineering, senior assistant in the group of Prof. Markus Rudin

02/2012-07/2014
Roche Glycart AG, Schlieren: team-leader “In Vivo Imaging” in the Preclinical Pharmacology Group, in charge of preclinical imaging activities (fluorescence and bioluminescence imaging, 2P microscopy)

09/2010-01/2012
Radboud University Medical Center, Nijmegen, Netherlands: EMBO postdoctoral fellow at the Department of Cell Biology in the research group of Prof. Peter Friedl, project title: “Microscopic visualization of the impact of tumor hypoxia on cancer invasion mode”

Publikationen

Publikationen vor Tätigkeit an der ZHAW

Lehmann S, Te Boekhorst V, Odenthal J, Bianchi R, van Helvert S, Ikenberg K, Ilina O, Stoma S, Xandry J, Jiang L, Grenman R, Rudin M, Friedl P. Hypoxia Induces a HIF-1-Dependent Transition from Collective-to-Amoeboid Dissemination in Epithelial Cancer Cells. Current biology : CB. 2017;27:392-400.

Herter S, Morra L, Schlenker R, Sulcova J, Fahrni L, Waldhauer I, Lehmann S, Reislander T, Agarkova I, Kelm JM, Klein C, Umana P, and Bacac M. A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents. Cancer immunology, immunotherapy : CII. 2017;66:129-40.

Lehmann S, Perera R, Grimm HP, Sam J, Colombetti S, Fauti T, Schaller T, Freimoser-Grundschober A, Zielonka J, Stoma S, Rudin M, Klein C, Umana P, Gerdes C, Bacac M. In vivo imaging of the activity of CEA TCB, a novel T-cell bispecific antibody, reveals specific tumor targeting and fast induction of T-cell mediated tumor killing. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016; 22(17):4417-27.

Commented by: Teijeira A, Etxeberria I, Ponz-Sarvise M, Melero I. Immunotherapy of Cancer Visualized by Live Microscopy: Seeing Is Believing. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016;22:4277-9.

Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Ouaret D, Bodmer W, Lehmann S, Hofer T, Hosse R, Moessner E, Ast O, Bruenker P, Grau-Richards S, Schaller T, Seidl A, Gerdes C, Perro M, Nicolini V, Steinhoff N, Dudal S, Neumann S, Hirschheydt T, Jaeger C, Saro J, Karanikas V, Klein C, Umana P. A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016; 22(13):3286-97.

Terry SY, Boerman OC, Gerrits D, Franssen GM, Metselaar JM, Lehmann S, et al. 11In-anti-F4/80-A3-1 antibody: a novel tracer to image macrophages. European journal of nuclear medicine and molecular imaging. 2015;42:1430-8.

Nagelkerke A, Bussink J, Mujcic H, Wouters BG, Lehmann S, Sweep FC, et al. Hypoxia stimulates migration of breast cancer cells via the PERK/ATF4/LAMP3-arm of the unfolded protein response. Breast cancer research : BCR. 2013;15:R2.

Dominietto M, Lehmann S, Keist R, Rudin M. Pattern analysis accounts for heterogeneity observed in MRI studies of tumor angiogenesis. Magnetic resonance in medicine. 2013;70:1481-90.

Lehmann S, Garayoa EG, Blanc A, Keist R, Schibli R, Rudin M. Recording intracellular molecular events from the outside: glycosylphosphatidylinositol-anchored avidin as a reporter protein for in vivo imaging. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2011;52:445-52.

Lehmann S, Stiehl DP, Honer M, Dominietto M, Keist R, Kotevic I, et al. Longitudinal and multimodal in vivo imaging of tumor hypoxia and its downstream molecular events. Proceedings of the National Academy of Sciences of the United States of America. 2009;106:14004-9.